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Brief cognitive assessmentCognitive impairment in schizophrenia and psychosis is ubiquitous and acknowledged as a core feature of
clinical expression, pathophysiology, and prediction of functioning. However, assessment of cognitive
functioning is excessively time-consuming in routine practice, and brief cognitive instruments speciﬁc to
psychosis would be of value. Two screening tools have recently been created to address this issue, i.e., the
Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in
Psychiatry (SCIP). The aim of this research was to examine the comparative validity of these two brief
instruments in relation to a global cognitive score. 161 patients with psychosis (96 patients diagnosed with
schizophrenia and 65 patients diagnosed with bipolar disorder) and 76 healthy control subjects were
tested with both instruments to examine their concurrent validity relative to a more comprehensive
neuropsychological assessment battery. Scores from the B-CATS and the SCIP were highly correlated in the
three diagnostic groups, and both scales showed good to excellent concurrent validity relative to a Global
Cognitive Composite Score (GCCS) derived from the more comprehensive examination. The SCIP-S showed
better predictive value of global cognitive impairment than the B-CATS. Partial and semi-partial
correlations showed slightly higher percentages of both shared and unique variance between the SCIP-S
and the GCCS than between the B-CATS and the GCCS. Brief instruments for assessing cognition in
schizophrenia and bipolar disorders, such as the SCIP-S and B-CATS, seem to be reliable and promising tools
for use in routine clinical practice.n Psiquiátrica, Hospital Virgen
ain. Tel.: +34 848 429400;
uesta).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Cognitive impairment in schizophrenia and bipolar disorder is ubiq-
uitous and recognized as fundamental to both the pathophysiology of
these disorders and the prediction of activities of daily living and
community functioning (Green et al., 2004, 2005; Tabarés-Seisdedos
et al., 2008). There is growing evidence that cognitive impairments are
not only detectable before illness onset and stable over time but are also
138 M.J. Cuesta et al. / Schizophrenia Research 130 (2011) 137–142shared by ﬁrst-degree relatives and heritable irrespective of psycho-
pathological diagnosis. Therefore cognitive impairments are among the
most promising candidate endophenotypes (Heinrichs and Zakzanis,
1998; Toulopoulou et al., 2007) either of psychosis or its premorbid
stages, such as early or transitional phase of psychosis (Heinrichs and
Zakzanis, 1998; Brewer et al., 2005).
Neuropsychological deﬁcits are highly prevalent in schizophrenia
and bipolar disorder (Daban et al., 2006; Krabbendam et al., 2005;
Seidman et al., 2010) and other psychoses, such as schizoaffective
disorder (Reichenberg et al., 2009). Although there is still considerable
debate regarding the extent to which cognitive deﬁcits and psycho-
pathological symptoms are related, recent reviews and meta-analyses
suggest that cognitive impairment and symptoms in schizophrenia are
independent or semi-independent dimensions of the illness, since only
small to medium signiﬁcant statistical associations between negative
and disorganization dimensions of psychosis and cognitive impairment
have been found (Dominguez et al., 2009; Nieuwenstein et al., 2001;
Ventura et al., 2000).
Until recently, schizophrenia patients were evaluated by means of
extensive neuropsychological batteries speciﬁcally designed for
neuropsychiatric disorders. There were few brief, valid, and reliable
instruments for assessing cognitive functioning by non-trained
clinicians in clinical practice. At present, there are speciﬁc neuropsy-
chological batteries available for schizophrenia and other psychoses,
such as the Cognistat (Kiernan et al., 1987), before 1995 known as the
Neurobehavioral Cognitive Status Examination; the Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS)
(Randolph et al., 1998); the Woodcock–Johnson III Test of Cognitive
Abilities (Woodcock et al., 2001); and the Brief Assessment of
Cognition in Schizophrenia (BACS) (Keefe et al., 2004; Segarra et al.,
2010). Despite the fact that these instruments have excellent psy-
chometric properties, their administration is quite time-consuming
(more than 30 min), diminishing its utility in psychiatric practice.
More abbreviated cognitive assessment instruments could offer an
important screening tool for cognitive deﬁcits in psychiatric illnesses,
and potentially encourage the monitoring of change over time and
treatment. This subject was addressed by clinicians working with
dementia and other neuropsychiatric and neurological illnesses years
ago with the introduction of standard brief measures, such as the
Mini-Mental State Examination (Folstein et al., 1975), now widely
used and well validated. In recent years, various brief screening tools
have been devised to assess cognition in psychiatric samples with the
intention of reducing administration time and bringing it into line
with the demands of a typical clinical practice. Examples are the Brief
Cognitive Assessment (BCA) (Velligan et al., 2004), the Screen for
Cognitive Impairment in Psychiatry (SCIP) (Purdon, 2005); and the
Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) (Hurford
et al., 2009). These all are simple and easy-to-administer instruments
that require minimal additional equipment and have shown goodTable 1
Cognitive domains and neuropsychological tasks of BCA, B-CATS, and SCIP.
Cognitive domain Neuropsychological tests
Motor and processing speed and attention Trail making test — part A
Digit symbol coding (WAIS
SCIP processing speed test
Verbal memory and learning Hopkins verbal learning tes
SCIP verbal learning test —
SCIP verbal learning test —
Fluency Letter ﬂuency test
Category ﬂuency test
SCIP letter ﬂuency
Executive functioning and set-shifting Trail making test — part B
SCIP working memory
BCA: Brief Cognitive Assessment; B-CATS: Brief Cognitive Assessment Tool for Schizophrenpsychometric properties (Guilera et al., 2009; Hurford et al., 2009;
Pino et al., 2008; Purdon, 2005; Rojo et al., 2010; Velligan et al., 2004).
Until their advent, there were no such instruments designed for
detecting cognitive deﬁcits in psychiatric disorders in only 15 min per
patient.
As shown in Table 1, both BCA and B-CATS are made up of
elements from other tests (e.g., Trail Making Test), while the SCIP is an
independent instrument. The BCA, B-CATS, and SCIP share the
assessment of key domains of cognitive impairment in psychiatric
illnesses. The SCIP and the BCA have subtests of processing speed and
attention, verbal memory and learning, verbal ﬂuency, and executive
functioning and set-shifting. The B-CATS assesses all these cognitive
domains with the exception of verbal memory and learning.
The development of brief instruments should include the study
of their comparative validity to reliably summarize and concisely
communicate information about a patient's overall level of cognitive
functioning. Despite its unquestionable value, the BCA had not
generated further studies after its initial publication, and its impact on
clinical practice and specialized literature was low. However, both the
CATS (and by extension its short version, the B-CATS) and the SCIP are
two instruments that seem tobewell accepted among clinicians and the
scientiﬁc community,with a promising future. In this context, the aimof
the current study was to examine for the ﬁrst time the comparative
validity of these brief cognitive screening instruments for schizophrenia
and psychosis (SCIP-S and B-CATS) in relation to a global cognitive score
derived from a more detailed assessment battery in patients with a
schizophrenia spectrum disorder or type I bipolar disorder.
2. Methods
2.1. Sample description
Samples were extracted from two original studies, with detailed
methods previously reported (Guilera et al., 2009; Pino et al., 2008).
The sample reported here was composed of all subjects from either
study who had complete data for all cognitive measures of interest,
excluding two bipolar patients with highly unusual values (i.e., time
to complete the TMT-Bmore than 6 min). The sample consisted of 237
participants, 96 patients with schizophrenia (86 schizophrenia, 9
schizoaffective disorders, and 1 schizophreniform disorder), 65 with
type I bipolar disorder, and 76 healthy controls. All subjects provided
informed written consent to participate and the studies were
approved by the Ethics Committee of the University of Barcelona.
Both patient groups were diagnosed according to DSM-IV criteria
(American Psychiatric Association, 2000). The control group was
interviewed with the Comprehensive Assessment of Symptoms and
History (CASH) (Andreasen et al., 1992). The patients who had
withdrawn from the previous studies, and were not included in the
present analysis, did not differ with respect to socio-demographicBrief cognitive instruments
BCA B-CATS SCIP
X
) X
X
t X
immediate X
delayed X
X
X X
X
X X
X
ia; SCIP: Screen for Cognitive Impairment in Psychiatry.
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clinical characteristics (illness duration, hospital admissions, and
mania/depression phases) from the patients remaining in the study,
in either the schizophrenia or bipolar subgroup (chi-square and t tests
with pN0.05). Table 2 lists the main socio-demographic and clinical
characteristics of the sample. When comparing socio-demographic
characteristics between groups, statistically signiﬁcant differences
were found in all comparisons (chi-square and analysis of variance
with pb0.05) except for educational level, while no statistically
signiﬁcant differences were observed between patient groups when
comparing clinical variables (illness duration, admissions, and
depression symptoms) (t tests with pN0.05), except for level of
depressive symptomatology (t(151)=3.811, pb0.05).
2.2. Cognitive assessments
A full neurocognitive assessment comprising attention, memory,
executive function, processing speed, and premorbid intelligence was
carried out. The battery included the following thirteen neuropsy-
chological measures: the Wechsler Adult Intelligence Scale-III
(Wechsler, 1999) subtests of Arithmetic, Digit Span (total score),
Digit Symbol-Coding, Letters and Numbers Sequencing, Symbol
Search (total score) and Vocabulary, the Wechsler Memory Scale-III
(Wechsler, 2004) subtests of Word list I (total words recalled) and
Word list II (total words recalled), the Trail Making Test (Army
Individual Test Battery, 1944) parts A and B (time), Semantic Fluency
(Estes 1974; Rosen 1980) and categories and percentage of iterative
errors on the Wisconsin Card Sorting Test (WCST) (Berg, 1948;
Heaton et al., 1993). Additionally, one of the three parallel forms of the
SCIP-S was administered to the entire sample. Patient neuropsycho-
logical subtest scores were standardized according to the cognitive
performance of the healthy control group. Bearing in mind the
purpose of the study, three neuropsychological measures wereTable 2
Socio-demographic and clinical descriptives by diagnosis.
Variable Schizophrenia Bipolar Healthy
controls
Mean SD Mean SD Mean SD
Age 37.03 8.77 41.23 10.07 37.91 8.59
Illness duration (months) 144.91 97.66 152.11 104.14 – –
Admissions 2.58 3.80 3.31 4.49 – –
HAM-D 5.35 3.23 3.44 2.77 – –
PANSS-P 10.15 3.53 – – – –
PANSS-N 16.81 6.33 – –
PANSS-G 25.78 6.94 – –
YMRS – – 1.84 2.84 – –
Mania/depression – – 4.46/4.46 3.62/4.54 – –
Variable n % n % n %
Sex
Males 70 72.9 32 49.2 44 57.9
Females 26 27.1 33 50.08 32 42.1
Marital status a
Single 82 85.4 29 44.6 17 22.4
Non-single, widow/er,
separated or divorced
14 14.6 36 55.4 37 48.6
Educational level
Primary education 37 38.5 23 35.4 25 32.9
Secondary education 40 41.7 23 35.4 30 39.5
University education 17 17.7 18 27.7 21 27.6
Other 2 2.1 1 1.5 0 0.0
Employment status a
Employed (or student) 27 28.1 22 33.9 51 67.1
Unemployed (or retired) 27 28.1 22 33.8 4 5.3
Disability 42 43.8 21 32.3 0 0.0
HAM-D: Hamilton Depression Scale; PANSS: Positive and Negative Syndrome Scale;
YMRS: Young Mania Rating Scale.
a Percentages are not 100% for the healthy controls due to missing data.created: a) the score on the B-CATS, b) the total score on the SCIP-S,
and c) a global cognition composite score (GCCS). The score on the
B-CATS was computed by averaging the standardized scores of the
subtests that compose it (Digit Symbol-Coding, Semantic Fluency, and
TMT-B time). The total SCIP-S score is provided directly by the scale,
and it was standardized according to the scores obtained by the
control group. Finally, the GCCS was obtained by computing the
average standardized scores for the remaining ten neuropsychological
measures after excluding the three components of the B-CATS.
2.3. Statistical analysis
Patient neuropsychological scores were standardized according
to the cognitive performance of the healthy control group. The GCCS,
B-CATS and SCIP-S scales were subsequently submitted to internal
consistency analyses by means of Cronbach's alpha method. The
relationship between the two cognitive measures (B-CATS and SCIP-S)
and the GCCS was examined with Pearson correlation coefﬁcients. In
addition, the B-CATS and SCIP-S were introduced as independent
variables in a stepwise regression analysis to quantify the amount of
explained variance in GCCS scores within each diagnostic group. Total
variance for each model (R2), and changes in R2 resulting from the
addition of predictors, were also calculated. Moreover, since both the
SCIP-S and B-CATS are brief general cognitive assessment instruments
anticipated to produce highly correlated scores, partial and semi-partial
correlations were calculated to distinguish shared and unique variance
in relation to the GCCS. By squaring both the partial correlation, the
resulting R2 determination coefﬁcient can be interpreted in terms of
proportion of theGCCS variance explainedby a predictor after removing
the inﬂuence of other predictors on both the GCCS and the predictor.
Along the same lines, by squaring the semi-partial correlation, it is
possible to infer the unique explained variance of the predictor on the
GCCS after removing the inﬂuence of other predictors in the criterion
variable (Hair et al., 2006). Lastly, multicollinearity that may affect the
regressionmodels was evaluated bymeans of a variance inﬂation factor
(VIF) following the criteria of Kleinbaum et al. (1988), inwhich VIF≥10
would suggest collinearity problems.
Additionally, an analysis based on the receiver operating charac-
teristic (ROC) curve was carried out in order to evaluate the ability of
the B-CATS and SCIP-S to discriminate between cognitively and non-
cognitively impaired individuals. Thus, the total sample was binary
stratiﬁed based on the impairment demonstrated on the GCCS,
establishing the cut-off point at ≤−1 standard deviation below the
normal mean. Several indicators were obtained, i.e., area under the
curve (AUC) and its conﬁdence interval, sensitivity and speciﬁcity
values, positive and negative likelihood ratios (+LR and −LR,
respectively), and positive and negative predictive values (PPV and
NPV, respectively).
Analyses were performed using SPSS software version 17.0, with a
signiﬁcance level of α=0.05.
3. Results
Means and standard deviations of B-CATS and SCIP-S total scores,
and GCCS for each diagnostic group are shown in Table 3. Schizophrenia
and bipolar patients performed between 1 and 1.5 standard deviations
lower than the healthy controls on all three cognitive measures.
The reliability analyses demonstrated good internal consistency
for GCCS in three comparison groups (Cronbach's alpha of .83, .82, and
.81, respectively for schizophrenia, bipolar, and control healthy
groups). Reliabilities were moderate for SCIP-S (alpha of .74, .79,
and .67, respectively) and questionable tomoderate for B-CATS (alpha
of .55, .60, and .71, respectively for schizophrenia, bipolar and control
healthy groups).
Table 4 presents the Pearson correlation coefﬁcients between
GCCS, B-CATS, and SCIP-S for each diagnostic group. GCCS signiﬁcantly
Table 5
Stepwise regression analyses with GCCS as criterion and B-CATS and SCIP-S as
predictors.
Group Variable B Standard error t test
Schizophrenia SCIP-S .36 .06 6.37⁎⁎
B-CATS .29 .06 4.58⁎⁎
Bipolar SCIP-S .27 .07 3.92⁎⁎
B-CATS .25 .08 3.09⁎
Healthy controls SCIP-S .26 .06 4.29⁎⁎
B-CATS .22 .08 2.91⁎
B-CATS: Brief Cognitive Assessment Tool for Schizophrenia; SCIP-S: Screen for Cognitive
Impairment in Psychiatry — Spanish version.
⁎⁎ pb .001.
⁎ pb .01.
Table 3
Cognitive performance by diagnosis.
Cognitive
measure
Schizophrenia Bipolar Healthy controls
Mean SD Mean SD Mean SD
GCCS −1.16 0.91 −1.22 0.93 0.01 0.60
B-CATS −1.50 1.12 −1.44 1.03 0.03 0.79
SCIP-S −1.46 1.28 −1.35 1.37 −0.01 1.02
GCCS: Global Cognitive Composite Score without B-CATS subtests; B-CATS: Brief
Cognitive Assessment Tool for Schizophrenia; SCIP-S: Screen for Cognitive Impairment
in Psychiatry — Spanish version.
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patients, bipolar patients, and normal healthy controls. Values ranged
from .57 (B-CATS and GCCS in type I bipolar disorder) to .76 (SCIP-S
and GCCS in schizophrenia). No signiﬁcant differences were found in
Pearson correlation coefﬁcients between the two short forms and the
global cognitive score (B-CATS/GCCS versus SCIP-S/GCCS) for schizo-
phrenia, bipolar, and healthy control groups.
The stepwise regression models indicated that both the B-CATS
and SCIP-S jointly accounted for between 45 and 65% of the GCCS
variance, with slight differences for each diagnostic group. The SCIP-S
was the ﬁrst signiﬁcant predictor to enter the three regression
equations (Table 5), and alone accounted for 58, 38, and 40% of the
variance in GCCS scores of the schizophrenia, bipolar, and control
healthy groups, respectively. Supplemental entry of the B-CATS to the
regression model also resulted in signiﬁcant changes in R2 (i.e.,
changes of .08, .09, and .06 for the three groups, respectively)
resulting in global R2 values of .66, .47, and .46.
To account for shared and unique contributions to GCCS variability
across diagnostic groups, partial and semi-partial correlations from
the regression analyses were examined. Partial correlation represents
the correlation between the GCCS and B-CATS after common variance
with the SCIP-S has been removed from both the GCCS and the B-
CATS. In contrast, semi-partial correlation represents the correlation
between GCCS and B-CATS once the variance in common with the
SCIP-S has been removed from the B-CATS but not from the GCCS.
Similarly, the two latter analyses were also applied to the correlations
(partial and semi-partial) between the GCCS and SCIP-S. Table 6
shows the partial and semi-partial correlation coefﬁcients between
the GCCS and both the B-CATS and the SCIP-S.
The semi-partial correlations indicated that the SCIP-S uniquely
accounted for 15%, 14%, and 14% of the variance in GCCS in the
schizophrenia, bipolar, and healthy control groups, whereas B-CATS
uniquely accounted for 8%, 9%, and 6%, respectively, of the variability
of the GCCS. No multicollinearity (tolerance and VIF statistics) among
measures was found.
The ROC analyses showed that, in the case of B-CATS, the AUC was
.866 (.820–.912 95% CI) and for the SCIP-S it was .895 (.849–.940 95%
CI), and both were signiﬁcantly different from 0.5 (pb .05). Further-
more, there were no statistically signiﬁcant differences between areasTable 4
Pearson correlation coefﬁcients between GCCS, B-CATS and SCIP-S scores.
B-CATS SCIP-S total score
Schizophrenia Bipolar Healthy
controls
Schizophrenia Bipolar Healthy
controls
GCCS .716 .572 .573 .764 .692 .658
SCIP-S
total score
.549 .507 .568 – – –
GCCS: Global Cognitive Composite Score without B-CATS subtests; B-CATS: Brief
Cognitive Assessment Tool for Schizophrenia; SCIP-S: Screen for Cognitive Impairment
in Psychiatry — Spanish version.
No signiﬁcant differences were found in Pearson correlation coefﬁcients between the
two short forms and the global cognitive score (B-CATS/GCCS versus SCIP-S/GCCS) for
schizophrenia, bipolar, and healthy control groups.under the ROC curve (z=1.131, p=0.26). Table 7 shows the
sensitivity and speciﬁcity, the likelihood ratios, and the predictive
values for most plausible different cut-off points (with a sensitivity
value of nearly 80 or more). It is worth remembering that screening
tests, such as the B-CATS and SCIP-S, must show high sensitivity and a
high NPV in order to minimize the rate of false negatives, even if this
leads to a certain increase in the number of false positives. In this
sense, both scales show satisfactory results, but there are small
differences depending on the cut-off point chosen.4. Discussion
Our results, in this novel research on subjects with a schizophrenia
spectrum disorder or type I bipolar disorder, indicate that both the B-
CATS and the SCIP-S scales are brief cognitive assessment tools with
acceptable reliability and concurrent validity. Good to excellent
concurrent validity was demonstrated by the good concordance
between each of these scales and a GCCS. There were certain
discrepancies in severity of impairment between performance in the
longer battery and in the brief instruments in the three diagnostic
groups and this discrepancy was higher for bipolar than for
schizophrenia patients. While the ﬁrst might suggest a relative excess
of ‘positives’ in patients showing impairment in cognitive perfor-
mance for the two brief cognitive tests, with regard to the longer
battery, this fact would suggest that the two brief instruments
probably capture a higher number of ‘positives’ (cognitive impair-
ment) which, as is common with screening instruments, may to some
extent be attributable to false positives. Comparatively, the SCIP-S
showed similar performance in schizophrenia, bipolar and healthy
control subjects. As expected, the amount of unique variance in the
GCCS explained by either the SCIP-S or the B-CATS was lower than the
shared or the global variance explained in the regression equations.
The SCIP-S contributed a slightly greater amount of unique variance to
the GCSS than did the B-CATS in all three diagnostic groups although
both have similar correlations with GCSS and similar AUC values in
the three diagnostic groups. Slight superiority in alpha coefﬁcients for
SCIP regarding B-CATS might in part be due to the fact that SCIP
included a higher number of tests than B-CATS. Regarding decision
validity, both scales showed good ability to differentiate between
individuals with and without cognitive impairment in terms of a
global measure of cognitive functioning.
Hurford et al. (2009) demonstrated that the B-CATS is a brief
cognitive instrument composed of well-known cognitive subtests
with adequate psychometric properties. In fact, it appears to be a good
choice for screening cognitive impairment in schizophrenia. The
original English version of the SCIP and its Spanish translation (the
SCIP-S) show good equivalence of their three alternate forms, good
internal consistency, and good test–retest reliability in both healthy
control and clinical samples (Pino et al., 2008; Purdon, 2005). In
addition, the SCIP-S seems to be a valid instrument for the detection of
Table 6
Partial and semi-partial correlations between GCCS and both B-CATS and SCIP-S scores.
Group Partial correlations (r)/variance explained (R2) Semi-partial correlations (sr)/variance explained (sr2) Collinearity
GCCS and B-CATS GCCS and SCIP-S GCCS and B-CATS GCCS and SCIP-S Tolerance VIF
Schizophrenia .44/.19 .56/.31 .28/.08 .39/.15 .57 1.75
Bipolar .38/.14 .46/.21 .30/.09 .38/.14 .74 1.35
Healthy controls .32/.10 .45/.20 .25/.06 .37/.14 .66 1.51
GCCS: Global Cognitive Composite Score without B-CATS subtests; B-CATS: Brief Cognitive Assessment Tool for Schizophrenia; SCIP-S: Screen for Cognitive Impairment in
Psychiatry — Spanish version.
141M.J. Cuesta et al. / Schizophrenia Research 130 (2011) 137–142cognitive deﬁcits in schizophrenia (Pino et al., 2008; Rojo et al., 2010)
and type I bipolar disorder (Guilera et al., 2009).
The SCIP and the B-CATS are pen and pencil instruments, with an
average administration time of between 12 and 15 min. They do not
require a computer for administration, and they are easily scored
manually. Thus, the B-CATS and the SCIP seem to be good candidates
as auxiliary assessment tools for the screening of cognitive impair-
ment, and they could provide clinicians with meaningful data
regarding their patients' global cognitive function. In contrast to a
complete neuropsychological evaluation, professionals from various
clinical backgrounds could easily be trained to administer the B-CATS
and the SCIP, although supervision by a licensed psychologist is
strongly recommended. Both instruments are relatively new, but
normative data are available and additional investigations are
ongoing to validate the tools for applications to clinical populations.
Brief cognitive screening instruments will never replace the diagnos-
tic andmonitoring value of a full neuropsychological examination, but
they could certainly offer a great deal of value to clinicians working
with patients with psychotic disorders, particularly if the diagnostic
criteria for schizophrenia are adapted to include reference to
quantiﬁed cognitive deﬁcits (Keefe, 2008; Barch and Keefe, 2010).
Practical considerations of cost and efﬁciency are important in the
selection of an instrument for evaluation of cognitive deﬁcits,
particularly given the large number of psychiatric patients (approx-
imately 2% of the general population) that could beneﬁt from a
screening examination. The B-CATS and the SCIP provide reliable and
valid results in approximately 15 min. The two tests have some
similarities, including somewhat similar tests of visuomotor tracking
and verbal ﬂuency, but the SCIP also includes tests of verbal working
memory, immediate verbal list learning, and delayed verbal list recall.
The B-CATS is made up of elements of other tests, and is thus subject
to costs and conditions of the corresponding psychological testingTable 7
Criterion values and indicators of the ROC curve for B-CATS and SCIP-S.
Criterion Sensitivity (95% CI) Speciﬁcity (95% CI) +LR −LR PPV NPV
B-CATS
≤−1.07 79.07 (69.0–87.1) 75.18 (67.2–82.1) 3.19 0.28 66.0 85.5
≤−1.04 81.40 (71.6–89.0) 75.18 (67.2–82.1) 3.28 0.25 66.7 86.9
≤−1.01 81.40 (71.6–89.0) 74.47 (66.4–81.4) 3.19 0.25 66.0 86.8
≤−1.00 82.56 (72.9–89.9) 74.47 (66.4–81.4) 3.23 0.23 66.4 87.5
≤−0.97 84.88 (75.5–91.7) 73.76 (65.7–80.8) 3.23 0.20 66.4 88.9
≤−0.96 86.05 (76.9–92.6) 73.05 (64.9–80.2) 3.19 0.19 66.1 89.6
SCIP-Sa
≤68 79.07 (69.0–87.1) 84.40 (77.3–90.0) 5.07 0.25 75.6 86.9
≤69 81.40 (71.6–89.0) 81.56 (74.2–87.6) 4.41 0.23 72.9 87.8
≤70 83.72 (74.2–90.8) 78.01 (70.3–84.5) 3.81 0.21 69.9 88.7
≤71 88.37 (79.7–94.3) 75.18 (67.2–82.1) 3.56 0.15 68.5 91.4
≤72 89.53 (81.1–95.1) 72.34 (64.2–79.5) 3.24 0.14 66.4 91.9
≤73 90.70 (82.5–95.9) 68.09 (59.7–75.7) 2.84 0.14 63.4 92.3
B-CATS: Brief Cognitive Assessment Tool for Schizophrenia; SCIP-S: Screen for Cognitive
Impairment in Psychiatry — Spanish version.
CI: conﬁdence interval; +LR: positive likelihood ratio; −LR: negative likelihood ratio;
PPV: positive predictive value; NPV: negative predictive value.
a Standardized scores were converted to raw scores because, unlike the B-CATS, the
SCIP directly provides a total raw score, which is more easily interpretable.corporations. In contrast, the SCIP is an independent instrument that,
although subject to copyright, at the time of publishing this
manuscript, can be obtained directly from the authors.
The brief instruments for assessment of cognitive deﬁcits in
schizophrenia and other psychosis were not designed for differential
diagnosis of cerebral pathology or for the prediction of socio-vocational
limitations resulting from cognitive deﬁcits, both ofwhich should be left
to professionals with expertise in clinical neuropsychology. However,
the brief screening tools appear to have somevalue for the estimation of
global cognitive deﬁcits apparent in psychosis patients. For example, a
ROC curve analysis of the sensitivity and the speciﬁcity of the SCIP-S
supported its use for differentiation between cognitively and non-
cognitively impaired samples in schizophrenia, bipolar disorder, and
healthy controls (Rojo et al., 2010). Further studies of sensitivity and
speciﬁcity will be necessary for the other cognitive screening tools.
Our results were in keepingwith baseline cognitive examination of
the large data set comprising 1493 patients with chronic schizophre-
nia enrolled in the CATIE schizophrenia trial (Keefe, 2008). This study
revealed that one of the measures collected in the CATIE battery
(WAIS-R digit symbol) accounted for 61% of the variance in the total
score. Moreover, a composite score resulting from the average of digit
symbol conjointly with other 5 subtests (list learning, grooved
pegboard, letter–number sequencing, verbal ﬂuency, and a maze
task) accounted for 93% of the variance in the global cognitive score
(Keefe, 2008).
One limitation of the present study concerns the battery chosen for
use as the gold standard. We are aware that it does not explore all the
cognitive domains impaired in functional psychoses (e.g., social
cognition). Future studies must therefore explore whether B-CATS
and SCIP performance could be related to other cognitive domains
that are not directly assessed by the test. In addition, SCIP results in
psychosis populations should be complemented by ecological mea-
sures of current functioning in the community. Kraus and Keefe
(2007) rightly suggest that the low face validity of many assessments
of cognitive functioning in patients with schizophrenia calls for the
co-administration of appropriate measures of functional outcome,
such as interview-based and functional proxy measures. It will also be
important to further examine the sensitivity of the B-CATS and the
SCIP to changes with treatment, particularly in the context of clinical
trials assessing cognitive-enhancing properties of novel treatments,
and in the assessment of beneﬁts claimed from various cognitive
retraining products that are now available or soon to be published. In
conclusion, despite the above limitations, the two screening tools
offer a relatively simple and inexpensive assessment that could be
adapted to mass testing if proven sensitive to change over time.
Another limitation of our study concerns the low internal consistency
coefﬁcients of B-CATS and SCIP across diagnostic groups. These low
alphas should be interpreted in view of several factors: a) the
particular test length involved (Cronbach alpha will be higher for
longer tests than for shorter tests); b) the context of degree of
heterogeneity in performance in each of the groups involved (samples
with small variability on the trait will give a smaller alpha than
samples with wide variability in traits), and obviously the fact that in
the present study, the reliability of each group is analyzed separately
which means that the variability decreases; and c) constraints related
142 M.J. Cuesta et al. / Schizophrenia Research 130 (2011) 137–142to different measurement errors of tests included within B-CATS and
SCIP (Gruijter and van der Kamp, 2008; Streiner, 2003).
In summary, the B-CATS in schizophrenia and the SCIP in
schizophrenia and bipolar disorder patients seem to be appropriate
tools for brief cognitive assessment in clinical practice, since they
reduce the time and resources required for complete neuropsycho-
logical assessment and can provide almost as much information as
longer batteries for calculating global cognitive performance.
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